Briakinumab Biosimilar – Research Grade: HRP

Trastuzumab Biosimilar – Research Grade

Horse Radish Peroxidase (HRP)

CD30

n/a

Human IgG1(E356D/M358L)-Kappa

Receptor tyrosine-protein kinase erbB-2, MLN 19, HER2, HER2/neu

CHO Cells

Human

Detects human CD30. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Our Briakinumab biosimilar is for research use only (RUO).

Briakinumab is a humanized Human IgG1(E356D/M358L)-Kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Briakinumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary).

0.5 mg/ml

This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 – 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase).

This HRP conjugate is stable when stored at 2-8°C. Do not freeze.

Flow Cytometry, ELISA

Each investigator should determine their own optimal working dilution for specific applications.